RESEARCH ARTICLE Open Access Efficacy of platinum-based

Full list of author information is available at the end of the articleLung cancer is the leading cause of cancer deaths among men and women worldwide [1]. Fewer than 20 % of patients diagnosed with lung cancer are candidates for surgical resection. Among patients who are candidates for surgical resection, the proportion with early stage non-small cell lung cancer (NSCLC) has increased due to surveillance programs and use of low-dose computed for stage I NSCLC is complete surgical resection with me-diastinal lymph node dissection. However, although the overall survival for stage IA NSCLC has been reported to be up to 73-90 % with surgical treatment only [3,4], the overall survival for pathologically staged T2aN0M0 stage IB NSCLC remains low, at approximately 60 % [4]. This modest and unsatisfactory result for node-negative NSCLC has been a source of frustration, and the possible use of adjuvant treatment after surgical resection for stage IB NSCLC has recently attracted interest among thoracic surgeons and oncologists